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Abstract:
Background: Previous studies investigating the association between 
anticholinergic burden (ACB) and health-related quality of life (HRQoL) 
showed conflicting results and focused on older adults or specific patient 
groups only. 
Methods: Participants from the European Prospective Investigation of 
Cancer Norfolk. study were divided into three groups according to their 
ACB from medications at baseline, representing ACB scores of 0, 1 and 
≥2. Outcomes of interest were the physical and mental component 
summary scores (PCS and MCS) of the Short Form-36, collected at 18 
months from the baseline and again after a mean 13 years of follow-up. 
Linear regression and logistic regression for cross-sectional and 
longitudinal associations between ACB and HRQoL were constructed 
adjusting for potential confounders. 
Results. A total of 16,675 participants, mean age 58.9±9.1 years 
(55.6% female) and 7133 participants, mean age at follow-up 69.1±8.7 
years (56.8% female), were included in the cross-sectional and 
longitudinal analysis, respectively. In cross-sectional analysis higher 
anticholinergic burden was associated with higher odds of being in the 
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lowest quartile of PCS (ACB=1: OR 1.85[1.64, 2.09] and ACB>2: 
2.19[1.85, 2.58] and MCS (ACB=1:1.47[1.30, 1.66] and 
ACB>2:1.68[1.42, 1.98]).  In longitudinal analysis higher anticholinergic 
burden was similarly associated with higher odds of being in the lowest 
quartile of PCS (ACB=1: 1.56[1.24, 1.95] and ACB>2: 1.48[1.07, 2.03]) 
compared to ACB 0 group. The association with MCS scores did not reach 
statistical significance. 
Conclusion The use of anticholinergic medications is associated with both 
short and long-term poorer physical function but association with mental 
functioning appears more short-term. 
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Background: Previous studies investigating the association between anticholinergic burden 
(ACB) and health-related quality of life (HRQoL) showed conflicting results and focused on 
older adults or specific patient groups only.
Methods: Participants from the European Prospective Investigation of Cancer Norfolk. study 
were divided into three groups according to their ACB from medications at baseline, 
representing ACB scores of 0, 1 and ≥2. Outcomes of interest were the physical and mental 
component summary scores (PCS and MCS) of the Short Form-36, collected at 18 months 
from the baseline and again after a mean 13 years of follow-up. Linear regression and logistic 
regression for cross-sectional and longitudinal associations between ACB and HRQoL were 
constructed adjusting for potential confounders. 
Results. A total of 16,675 participants, mean age 58.9±9.1 years (55.6% female) and 7133 
participants, mean age at follow-up 69.1±8.7 years (56.8% female), were included in the 
cross-sectional and longitudinal analysis, respectively. In cross-sectional analysis higher 
anticholinergic burden was associated with higher odds of being in the lowest quartile of PCS 
(ACB=1: OR 1.85[1.64, 2.09] and ACB>2: 2.19[1.85, 2.58] and MCS (ACB=1:1.47[1.30, 
1.66] and ACB>2:1.68[1.42, 1.98]).  In longitudinal analysis higher anticholinergic burden 
was similarly associated with higher odds of being in the lowest quartile of PCS (ACB=1: 
1.56[1.24, 1.95] and ACB>2: 1.48[1.07, 2.03]) compared to ACB 0 group. The association 
with MCS scores did not reach statistical significance.
Conclusion The use of anticholinergic medications is associated with both short and long-
term poorer physical function but association with mental functioning appears more short-
term.
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Key messages
 Previous studies on anticholinergic burden (ACB) and health-related quality of life 
(HRQoL) have yielded conflicting results and been limited by small sample size.
 In the cross-sectional analysis of 16,675 participants, anticholinergic burden was 
independently associated with poorer physical and mental HRQoL.
 In the longitudinal analysis with 7133 participants we demonstrated that baseline 
anticholinergic burden predicted poorer physical HRQoL at 13 years follow-up.
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Polypharmacy is a common and growing phenomenon, especially in older people. 
Medications with anticholinergic properties are of special interest in this area, with up to 50% 
of the older population prescribed at least one such medicine (1). Anticholinergics have long 
been associated with potential adverse effects that can be caused by their cumulative burden. 
A systematic review by Fox et al. including 46 studies linked anticholinergics to decline in 
cognitive as well as physical function, with limited evidence associating them with mortality 
outcomes (2). Anticholinergics have also been associated with dry mouth, constipation and 
blurred vision (3), with recent studies linking them to risk of falls (4) as well as stroke (5). 
However, few studies have investigated the impact of anticholinergic burden on patients’ 
health-related quality of life and they are limited by small sample sizes as well as they only 
focused on patients with specific conditions (e.g. dementia) or specific populations (older 
adults only) (6-9).
Health-related quality of life (HRQoL) is an important health concept that measures the 
effects of health conditions on an individual’s subjective sense of physical and mental well-
being (10). HRQoL questionnaires such as Short-Form 36 (SF-36) represents an individual’s 
point of view on medical outcomes, something that is increasingly more valued (11). More 
generally, HRQoL based on self-reported physical and mental functional health using SF-36 
is viewed as a valid measure of health (12) and has also been reported as a predictor of both 
short-term and long-term adverse health outcomes (13).  
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Previous studies on HRQoL and anticholinergic burden (ACB) have yielded conflicting 
results (6-9).  One study reported no difference in the mean Short Form-8 score between 
patients with different ACB (9), another showed that a greater ACB was associated with 
lower physical HRQoL with no effect on mental HRQoL in people with dementia (7), while a 
recent longitudinal study demonstrated that an increase in ACB was associated with a 
statistically significant decrease in patient’s physical HRQoL and a statistically significant 
increase in mental HRQoL (6). 
Further studies with general populations over longer follow up using larger cohorts are 
needed to establish the link between ACB and HRQoL. This also has potential to validate 
HRQoL as an outcome measure in clinical trials assessing the clinical and cost effectiveness 
of ACB reduction strategies. This is particularly relevant as SF-36 can be converted to SF-
6D, which is an utility index (14). Additionally, HRQoL is a highly rated outcome measure 
relevant for clinical practice, so understanding relationships between ACB and HRQoL may 
help clinicians judge the risks and benefits of starting or stopping anticholinergic medications 
for a range of conditions. In this study, therefore, we aimed to examine the relationship 
between total anticholinergic burden (ACB) from medications at study baseline and 
participants’ self-reported physical and mental functional health from the SF-36 summary 
scores at 18 months from baseline and at 13-year follow up in a UK population-based study, 
the European Prospective Investigation of Cancer (EPIC)-Norfolk study. This study is 
representative of the British general population, with the exception of a lower proportion of 
current smokers (15).
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The participants were men and women between the ages of 39 and 79 years at baseline 
(1993-97), who took part in the EPIC-Norfolk study. The study protocol of EPIC-Norfolk has 
been previously described in detail (15). Briefly, participants were invited to participate from 
general practice age-sex registers in Norfolk, UK. In total, 25,639 participants (99.6% White 
British) attended a baseline health examination during 1993-97. The participants attended a 
health check after 13 years between 2004 and 2011, which included a total of 8623 
participants. Participants who did not return for follow-up were more likely to have been 
smokers, older, heavier, of lower socioeconomic status and have higher blood pressure at 
baseline (16). Norwich Ethics Committee approved the study and all patients provided 
written informed consent.
Measurements
Participants completed a health and lifestyle questionnaire at study baseline, which provided 
information on educational status, physical activity, smoking status, alcohol consumption, 
prevalent illness and medication. Physiological and biological parameters such as weight, 
height, blood pressure and non-fasting venous blood samples were collected by trained nurses 
during the clinic visit. 
Drugs associated with anticholinergic burden were identified by searching the database for 
exact and similar entries for both generic and brand name drugs. Each medication was 
assigned a corresponding anticholinergic burden (ACB) score. Classification of drugs with 
ACB was class 0 (none), class 1 (probable), classes 2 and 3 (definite) based on the criteria of 
Anticholinergic Cognitive Burden Scale from Boustani et al (17). The total anticholinergic 
burden was measured using the Anticholinergic Cognitive Burden scale with the formula of: 
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((number of class 1 anticholinergics) + (number of class 2 anticholinergics x 2) + (number of 
class 3 anticholinergics x 3)).  The distribution of ACB scores was skewed with most 
participants expressing an ACB of 0 (86 %). Therefore, participants were divided into three 
groups according to their ACB score at baseline (ACB=0, ACB=1 and ACB ≥2)
Outcome measures
The primary functional outcomes were the physical and mental component summary scores 
(PCS and MCS) of the Short form 36 (SF-36) collected at 18 months after study baseline and 
at 13 year follow up. The SF-36 assesses HRQoL in eight different areas: physical 
functioning, role-physical, bodily pain, general health, vitality, social functioning, role-
emotional and general mental health (11). Subcategory scores range from 0 to 100, with 
higher scores indicating better health status. These subcategories can be summarised to two 
summary scores- Physical Component summary (PCS) score and Mental Health Component 
summary (MCS) score.  These summary scores have been standardised using norm based 
methods (18). In a general U.S. population both PCS and MCS have a mean of 50 and 
standard deviation of 10 (18). These summary scores provide more coherent information in 
comparison to individual subcategory scores (19).
Exclusion criteria
Participants with incomplete baseline data were excluded from all analyses. For the main 
longitudinal analyses, participants were excluded if they did not return an SF-36 form at 13-
year follow-up.
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The statistical analyses were performed using SPSS version 24.0 (SPSS Inc., Chicago, IL, 
USA). Baseline sample characteristics are presented for the whole sample and by ACB 
groups. Differences between ACB groups were assessed using the chi-squared test for 
categorical variables and analysis of variance (ANOVA) for continuous variables. Linear 
regression was performed to determine the association of baseline ACB score and PCS and 
MCS scores at 18 months from baseline and 13 year follow up using ACB group 0 as 
reference category. Due to short term follow up between baseline clinic assessment and first 
SF-36 measurement we performed cross sectional analysis. Logistic regression models were 
constructed for both time points; both PCS and MCS were dichotomised using 25th centile 
values to provide estimates (odds) of being in the bottom quartile of the population health as 
representative of the individual having impaired physical or mental functional HRQoL (20). 
Separate models were constructed for both PCS and MCS as dependent variables with and 
without adjusting for covariates at study baseline. 
We constructed four models by incremental adjustment of clusters of co-variates.  
Model A was unadjusted, Model B was adjusted for age and sex, Model C was additionally 
controlled for sociodemographic and lifestyle factors including age, sex, social class, 
smoking status, alcohol use, educational level, physical activity, BP and BMI. Finally, in 
Model D we adjusted for variables in Model C as well as prevalent stroke, cancer, diabetes, 
asthma, arthritis, liver disease, depression and other psychiatric illness, all of which could 
potentially confound both predictor and outcome. For longitudinal analyses an additional 
Model E similar to Model D was constructed with confounders that may have changed during 
the follow up collected at 3HC (smoking status, alcohol use, physical activity, BP, 
comorbidities, BMI) in order  to address the participant’s current health status at 3HC.  A 
two-sided P-value <0.05 was considered statistically significant.
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From the 25,639 participants who attended the first health check for EPIC-Norfolk, 8964 
were excluded due to missing data (missing data table in supplementary data) on the variables 
included in this analysis leaving 16,675 participants. SF-36 scores were recorded for 19,535 
participants (64.2% of total EPIC-Norfolk sample). Not all participants who attended the 
baseline health check completed the SF-36 form and vice versa. Therefore, from the baseline 
health check attendees, the SF-36 physical health summary score (PCS) and mental health 
summary score (MCS) were the variables with most missing data (8480 participants had 
missing data for both PCS and MCS scores).
Cross-sectional analysis
Table 1 depicts sample characteristics at baseline by ACB groups. The mean age (SD) was 
58.9 years (9.1) and 55.6% of the participants were female. The mean (SD) PCS and MCS 
scores of the participants were 47.6 (10.1) and 52.3 (9.4), respectively. There were significant 
differences between ACB groups for almost all variables analysed. People in the higher ACB 
groups were older and of lower social class and educational level and had lower level of 
physical activity. In terms of comorbidities, high ACB was associated with higher blood 
pressure, and had higher prevalence of depression, arthritis and cancer. Significantly lower 
mean PCS and MCS scores were also observed in the higher ACB groups. 
Table 1 here
In the fully adjusted linear regression models (see Supplementary Table 1), the associations 
between higher ACB scores and lower PCS and MCS scores remained (all p<0.001). 
Table 2 demonstrates the results of binary logistic regression depicting the OR (95% CI) of a 
participant belonging to the bottom 25% of PCS and MCS scores at study baseline. 
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Participants in higher ACB groups had higher odds of belonging to the bottom quartile of 
both HRQoL summary scores. The differences were slightly attenuated after adjustment for 
potential confounders but remained significant. In the fully adjusted regression model 
ACB=1 was associated with an OR of 1.85 (95% CI 1.64, 2.09) (p<0.001) and ACB ≥ 2 an 
OR of 2.19 (95% CI 1.85, 2.58) (p<0.001) for being in the bottom PCS quartile compared to 
the ACB= 0 group.  The corresponding ORs (95%CI) for being in the bottom quartile of the 
MCS were 1.47 (1.30, 1.66) (p<0.001) and 1.68 (1.42, 1.98) (p<0.001), respectively.  
Table 2 here
Longitudinal analysis
Table 3 shows the characteristics of 7133 participants (56.8% female, mean (SD) age 69.1 
(8.7) years) who attended follow-up health check and completed another SF-36. The mean 
PCS score at follow up was slightly lower than baseline 47.1 (10.6) and mean MCS score was 
higher 54.3 (8.0). People in the higher ACB groups were older and had lower educational 
attainment, had higher blood pressure, were less physically active and more likely to have a 
baseline diagnosis of depression, arthritis and myocardial infarction. People in higher ACB 
groups had lower HRQoL scores for both summary scores.
Table 3 here
In the fully adjusted longitudinal linear regression models (available in supplementary data), 
the baseline ACB =1 group had lower PCS (β -3.0 (95%CI -3.9 - -2.0, p<0.001) and MCS 
scores (β -0.6 (95%CI  -1.3, 0.2, p=0.10) relative to those with ACB of zero. Baseline ACB ≥ 
2 was also associated with lower PCS (β -2.5 (95%CI -3.8 - -1.2, p<0.001) and MCS scores 
(β 1.5, 95%CI -2.6 - -0.4, p=0.007). In the subgroup analysis adjusting for confounders at 
follow-up, the results were broadly similar (Supplementary Table 2).
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Table 4 shows that participants with higher ACB scores at baseline had higher odds of being 
in the bottom quartile of both summary scores. In the fully adjusted model, ACB=1 was 
associated with an OR of 1.56 (95% CI 1.24, 1.95) (p<0.001) and ACB ≥ 2 an OR of 1.48 
(95% CI 1.07, 2.03) (p=0.017) for being in the bottom PCS quartile compared to the ACB= 0 
group. For MCS the adjustment for prevalent illnesses attenuated the results considerably. 
However an OR 1.27 (95% CI 1.01, 1.60) (p=0.042) was observed in the fully adjusted 
model for ACB=1 compared no ACB at baseline. Additional analysis adjusting for 
confounders measured at follow-up attenuated the results of ACB ≥ 2 group for both 
summary scores, but the ACB=1 group had an OR of 1.51 (95% CI 1.16, 1.97) (p=0.003) and 
1.50 (95% CI 1.15, 1.95) (p=0.002) for PCS and MCS respectively. 
Table 4 here
DISCUSSION
Our results demonstrate that participants with higher baseline anticholinergic burden (ACB) 
from medications had both lower PCS and MCS compared to those with no anticholinergic 
burden. The association remained after 13 years of follow up. The participant in the ACB 1 
and ACB ≥ 2 groups were older, of lower occupational social class and had lower level of 
educational attainment, had higher blood pressure and were less physically active and more 
likely to have a baseline diagnosis of conditions such as depression, arthritis or cancer. 
However, even after adjusting for these potential confounders, the differences remained 
statistically significant.  Baseline ACB =1 was associated with a decrease of 3.0 units 
[β(95%CI)] [-3.0 (-3.9, -2.0)] in the participant’s follow-up PCS scores compared to no ACB 
at baseline, while baseline ACB ≥ 2 showed a decrease of 2.5 units [-2.5(-3.8,-1.2)] in the 
PCS scores and decrease of 1.5 units [-1.5 (-2.6, -0.4)] in the MCS at follow-up. 
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Clinically important differences for individual SF-36 subcategories were determined to be in 
the range of 5.0–12.5 for asthma, chronic lung disease or heart disease by an expert panel 
(21). However, clinically minimally significant differences have not been defined for PCS 
and MCS scales due to computation and conceptual difficulties associated with these 
estimates (21). We therefore also examined the participant’s odds of having poor HRQoL 
(obtaining a score belonging to the bottom 25th percentile of PCS and MCS scores) in relation 
to anticholinergic exposure from medications. In the longitudinal analysis, compared to no 
ACB at baseline, those with remaining ACB categories had significantly higher odds ratios of 
1.56 (1.24, 1.95) 1.48 (1.07, 2.03) for being in the bottom quartiles of PCS at 3HC for ACB = 
1 and ACB ≥2, respectively. After adjustment for baseline illnesses the only association 
between ACB and being in bottom quartiles of MCS was observed in the ACB=1 group 
(OR=1.27 (1.01, 1.60)). In the additional analysis adjusting for confounders at follow-up, the 
ACB ≥ 2 group had a very small number of participants left (n=154), resulting in loss of 
power. 
The 95% CIs of the ACB =1 and ACB ≥ 2 groups overlap in results of most of the regression 
models, something that has been previously reported in a study on the effects of ACB on 
stroke (5). This may be a reflection of the sample size or perhaps indicate that the effects on 
HRQoL are driven by any level of exposure to anticholinergics, rather than the magnitude of 
the exposure. 
To our knowledge, amongst the studies which examined the association between ACB and 
HRQoL, this is the first study to include analysis of odds of participant’s scoring lower PCS 
and MCS scores in relation to exposure to anticholinergic medications. The novelty of this 
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study also lies in the UK based general population and a larger sample size. Previous studies 
have shown varying results perhaps related to smaller sample sizes.  A study of US 
community dwelling veterans reported no difference in the physical HRQoL (measured with 
SF-8) between participants (N=532) who were taking anticholinergic medications compared 
to those who were not (9). However, the use of anticholinergic medications measured with 
the ADS scale was linked to reduction in the physical HRQoL measured with the Australian 
World Health Organization Quality of Life questionnaire (WHOQOL-BREF) in a cohort 
study consisting of community dwelling elderly with and without dementia (N=1044) (8). A 
retrospective cohort study with 112 patients with dementia linked ACB measured with the 
ADS scale to 7.48 unit reduction in the PCS score of SF-12, without an effect on the MCS 
(7). In the most recent cohort study with community dwelling older adults (N=1793) an 
increase of 1 in the ACB was associated with a β value of -0.50 (95% CI -0.68, -0.31) in the 
PCS and a β value of 0.19 (95% CI 0.01, 0.37) in the MCS of the SF-36 during three year 
follow up period (6). Our results support these findings. 
However, the longitudinal analysis showed β value of-1.5 in MCS scores in ACB ≥ 2 group 
in linear models indicating decrease in MCS scores, in contrast to a previously reported slight 
increase in MCS with higher ACB. The previous study, however, consisted of a smaller 
Canadian cohort of older patients (N=1793) (6). Our results are intuitively more logical, and 
suggest the previous finding in older adults may be potentially attributable to selection bias, 
with older adults prescribed and able to tolerate anticholinergic drugs having higher MCS. In 
the fully adjusted model, the longitudinal association between higher ACB and lower MCS 
did not reach statistical significance, possibly due to a lower sample size and the effects of 
adjusting for depression and other psychiatric illnesses such as dementia, which could 
arguably be partly attributable to anticholinergic burden.
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Of note, previous studies on ACB and HRQoL have found a prevalence of anticholinergic 
drug use at 15% in a US study (7), 42% in another in Australia (8) and 33% in a Canadian 
population (6). In this study in a relatively unselected British cohort, anticholinergic drug use 
prevalence was 14% at the study baseline. These differences may be explained by the 
population settings, as one study consisted of only people with dementia while the others 
focused on older people.
Our study has several strengths. We used a large population-based cohort, which improves 
the generalizability of our results. This also allowed us to capture a sufficient number of 
individuals with high ACB and assess the differences in odds between participants with 
different degrees of ACB. We were able to control for variety of sociodemographic and 
lifestyle factors as well as comorbidities. We also used a well-validated ACB score against 
several health outcomes such as stroke, cardiovascular events, risk of falls and cognitive 
impairment (4,5,22,23). 
We also note some limitations. As a volunteer study with long-term follow up, a degree of 
healthy volunteer bias is possible. However, the baseline characteristics of the EPIC-Norfolk 
participants are similar to other UK representative population samples (15). Potential 
confounders were measured at baseline, and it is possible that these may vary during the 
follow-up period. To address this for the longitudinal analyses, we constructed a regression 
model adjusting for participant’s current health status at follow-up. Although we were able to 
calculate the total ACB, we were not able to identify particular drugs nor dosages linked to 
adverse outcomes. As ACB was calculated at baseline we do not know whether the 
participants continued taking the same medication regimen during the follow up period. The 
Page 31 of 42
http://mc.manuscriptcentral.com/pds































































assumption would be that individuals classified according to baseline ACB exposure would 
more or less maintain the same exposure during follow up or, if anything, ACB use would 
increase in all groups as the participants of an ageing cohort will accrue more disease burden 
and more polypharmacy. However, the measurement error in ascertainment of ACB exposure 
through individuals stopping or starting ACBs during the follow up time would be likely only 
to attenuate the observed relationships rather than produce spurious relationships.  A general 
limitation in this field is the use of at least 12 different scales for evaluating exposure to 
anticholinergic medications (3), which makes generalization and comparison of results 
difficult. 
Implications
The multiple guidelines available on management of polypharmacy recommend medications 
review and optimisation in collaboration with patients and multidisciplinary teams (24, 25). 
Although medications with anticholinergic properties play a key role in the management of 
certain diseases, minimizing anticholinergic burden should be considered when safer agents 
are available (24, 25). Being attentive to patient’s HRQoL and ACB should be important 
during clinical medication review and deprescribing medications with ACB prioritized when 
relevant HRQoL assessed with SF-36 could be used as an outcome measure in clinical trials 
assessing the clinical and cost effectiveness of ACB reduction strategies. 
Conclusion
Use of anticholinergic medications predicted poorer HRQoL in the EPIC-Norfolk general 
population, both at baseline and after a mean 13 years of follow-up. The association remained 
true after adjusting for multiple potential confounders, though maintained statistical 
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significance in all models only for physical health domains.  In the absence of long-term 
clinical trials examining the impact of reducing ACB, our results add to the growing evidence 
that offer incentive to clinicians and the public to use medications with anticholinergic 
properties with caution. Future studies should explore whether reducing the ACB has an 
effect on improving health outcomes, including HRQoL. 
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Never smoker 8030 (48.2) 7082 (49.1) 628 (41.8) 320 (42.2)













































Systolic BP (mmHG) (SD) 135.0 (18.0) 134.0 (18.0) 141.0 (18.0) 138.0 (19.0) <0.001
BMI (SD) 26.2 (3.9) 26.1 (3.8) 27.1 (4.0) 27.1 (4.4) <0.001
MI (%) 477 (2.9) 223 (1.5) 161 (10.7) 93 (12.3) <0.001
Stroke (%) 205 (1.2) 115 (0.8) 50 (3.3) 40 (5.3) <0.001
Cancer (%) 916 (5.5) 754 (5.2) 104 (6.9) 58 (7.7) 0.001
Diabetes (%) 354 (2.1) 246 (1.7) 74 (4.9) 34 (4.5) <0.001
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Asthma (%) 1370 (8.2) 1167 (8.1) 132 (8.8) 71 (9.4) 0.33
Arthritis (%) 3911 (23.5) 3195 (22.2) 477 (31.7) 239 (31.5) <0.001
Liver disease (%) 392 (2.4) 329 (2.3) 43 (2.9) 20 (2.6) 0.32
Depression (%) 2361 (14.2) 1887 (13.1) 199 (13.2) 275 (36.3) <0.001
Other psychiatric illness (%) 494 (3.0) 362 (2.5) 44 (2.9) 88 (11.6) <0.001
Mean PCS score (SD) 47.6 (10.1) 48.4 (9.5) 42.6 (11.3) 41.0 (12.2) <0.001
Mean MCS score (SD) 52.3 (9.4) 52.5 (9.1) 51.9 (10.0) 49.1 (11.9) <0.001
Values presented are mean (SD) for continuous and number (%) for categorical data. Total anticholinergic burden (ACB) was calculated with 
the formula of ((number of class 1 anticholinergics) + (number of class 2 anticholinergics x 2) + (number of class 3 anticholinergics x 3)). 
Classification of drugs with ACB was class 0 (none), class 1 (mild), classes 2 and 3 (severe) based on the Anticholinergic Cognitive Burden 
Scale. BP=blood pressure. BMI= body mass index. MI= myocardial infarction. PCS score= physical component summary score. MCS=mental 
component summary score. 
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Table 2. Binary logistic regression modelling of the odds ratios of participants belonging to the 25th centile of PCS (PCS<42.5) and MCS scores 
(MCS < 48.4) at baseline by ACB groups with ACB=0 as reference category.
ACB=0 ACB=1 ACB  ≥ 2
OR OR 95% C.I p OR 95% C.I p
PCS 
Model A 1.00 (ref) 2.65 (2.38, 2.96) <0.001 3.43 (2.96, 3.97) <0.001
Model B 1.00 (ref) 2.10 (1.87, 2.35) <0.001 2.86 (2.46, 3.33) <0.001
Model C 1.00 (ref) 1.94 (1.72, 2.17) <0.001 2.49 (2.13, 2.90) <0.001
Model D 1.00 (ref) 1.85 (1.64, 2.09) <0.001 2.19 (1.85, 2.58) <0.001
MCS
Model A 1.00 (ref) 1.33 ( 1.18, 1.49) <0.001 2.16 (1.86, 2.51) <0.001
Model B 1.00 (ref) 1.58 (1.40, 1.78) <0.001 2.49 (2.14, 2.90) <0.001
Model C 1.00 (ref) 1.54 (1.36, 1.74) <0.001 2.34 (2.00, 2.73) <0.001
Model D 1.00 (ref) 1.47 (1.30, 1.66) <0.001 1.68 (1.42, 1.98) <0.001
OR= odds ratio; C.I= confidence interval
Model A: unadjusted model
Model B:  adjusted for age and sex
Model C: as model B, additionally adjusted for social class, smoking status, alcohol use, educational level, physical activity, BP and BMI
Model D: as model C additionally adjusted for prevalent stroke, cancer, diabetes, asthma, arthritis, liver disease, depression and other psychiatric 
illness.
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Current smoker 595 (8.3) 542 (8.4) 27 (5.9) 26 (12.8)
0.001
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Alcohol use ( units/week) 
(SD)













































Systolic BP (mmHg) (SD) 132.2 (17.1) 131.2 (17.0) 138.6 (16.7) 134.8 (18.5) <0.001
BMI (SD) 25.8 (3.7) 25.7 (3.7) 27.0 (3.8) 26.7 (4.0) <0.001
MI (%) 102 (1.4) 51 (0.8) 38 (8.4) 13 (6.4) <0.001
Stroke (%) 52 (0.7) 36 (0.6) 11 (2.4) 5 (2.5) <0.001
Cancer (%) 360 (4.6) 287 (4.4) 28 (6.2) 15 (7.4) 0.04
Diabetes (%) 78 (1.1) 59 (0.9) 15 (3.3) 4 (2.0) <0.001
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Asthma (%) 564 (7.9) 508 (7.8) 41 (9.0) 15 (7.4) 0.60
Arthritis (%) 1406 (19.7) 1217 (18.8) 132 (29.1) 57 (28.1) <0.001
Liver disease (%) 170 (2.4) 150 (2.3) 18 (4.0) 2 (1.0) 0.04
Depression (%) 1008 (14.1) 852 (13.2) 61 (13.4) 95 (46.8) <0.001
Other psychiatric illness (%) 187 (2.6) 143 (2.2) 13 (2.9) 31 (15.3) <0.001
Mean PCS score at follow 
up(SD)
47.1 (10.6) 47.7 (10.2) 41.4 (12.5) 42.2 (12.3) <0.001
Mean MCS score at follow up 
(SD)
54.3 (8.0) 54.4 (7.8) 54.2 (8.5) 51.0 (10.7) <0.001
Mean ACB score at follow up 0.4 (0.9) 0.3 (0.8) 0.8 (1.2) 1.4 (1.7) <0.001
Values presented are mean (SD) for continuous and number (%) for categorical data. Total anticholinergic burden (ACB) was calculated with 
the formula of ((number of class 1 anticholinergics) + (number of class 2 anticholinergics x 2) + (number of class 3 anticholinergics x 3)). 
Classification of drugs with ACB was class 0 (none), class 1 (mild), classes 2 and 3 (severe) based on the Anticholinergic Cognitive Burden 
Scale. BP=blood pressure. BMI= body mass index. MI= myocardial infarction. PCS score= physical component summary score. MCS=mental 
component summary score.
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Table 4. Binary logistic regression models of the odds ratios of participants belonging to the 25th percentile of PCS scores (PCS<41.5) and MCS 
scores (MCS <51.3) at 13 year follow up by ACB groups with ACB=0 as reference category.
ACB=0 ACB=1 ACB  ≥ 2
OR OR 95% C.I p OR 95% C.I p
PCS
Model A 1.00 (ref) 2.64 (2.17, 3.20) <0.001 2.44 (1.84, 3.24) <0.001
Model B 1.00 (ref) 2.07 (1.68, 2.54) <0.001 2.45 (1.67, 3.03) <0.001
Model C 1.00 (ref) 1.86 (1.51, 2.30) <0.001 1.97 (1.46, 2.67) <0.001
Model D 1.00 (ref) 1.56 (1.24, 1.95) <0.001 1.48 (1.07, 2.03) 0.017
Model E 1.00 (ref) 1.51 (1.16, 1.97) 0.003 1.45 (1.00, 2.13) 0.054
MCS
Model A 1.00 (ref) 1.25 (1.01, 1.54) 0.038 1.77 (1.32, 2.37) <0.001
Model B 1.00 (ref) 1.35 (1.09, 1.67) 0.006 1.81 (1.35, 2.43) <0.001
Model C 1.00 (ref) 1.34 (1.08, 1.66) 0.008 1.73 (1.29, 2.33) <0.001
Model D 1.00 (ref) 1.27 (1.01, 1.60) 0.042 1.12 (0.81, 1.54) 0.49
Model E 1.00 (ref) 1.50 (1.15, 1.95) 0.002 1.12 (0.78, 1.61) 0.55
OR= odds ratio; C.I= confidence interval
Model A: unadjusted model
Model B:  adjusted for age and sex
Model C: as model B, additionally adjusted for social class, smoking status, alcohol use, educational level, physical activity, BP and BMI
Model D: as model C additionally adjusted for prevalent stroke, cancer, diabetes, asthma, arthritis, liver disease, depression and other psychiatric 
illness.
Model E: subgroup analysis of participants with follow-up covariate data (n=5685) as model D, however confounders (smoking status, alcohol 
use, physical activity, BP, comorbidities, BMI)  measured at follow-up.
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